These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28830318)

  • 41. A half-marathon run does not acutely influence lipoprotein(a).
    Lippi G; Schena F; Salvagno GL; Montagnana M; Guidi GC
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):e37-8. PubMed ID: 18472408
    [No Abstract]   [Full Text] [Related]  

  • 42. Corrections: Oxidized phospholipids associated with lipoprotein(a) contribute to hypofibrinolysis in severe aortic stenosis.
    Pol Arch Intern Med; 2024 Sep; 134(9):. PubMed ID: 39327985
    [No Abstract]   [Full Text] [Related]  

  • 43. Lipoprotein(a) and cardiovascular disease.
    Nordestgaard BG; Langsted A
    Lancet; 2024 Sep; 404(10459):1255-1264. PubMed ID: 39278229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum lipoprotein(a) as an independent cardiovascular risk factor for patients undergoing chronic hemodialysis.
    Docci D; Manzoni G; Baldrati L; Capponcini C; Neri L; Feletti C
    Nephron; 1995; 69(2):195. PubMed ID: 7723916
    [No Abstract]   [Full Text] [Related]  

  • 45. What do we know about lipoprotein(a)?
    Cybulska B; Kłosiewicz-Latoszek L
    Kardiol Pol; 2015; 73(4):235-9. PubMed ID: 25563463
    [No Abstract]   [Full Text] [Related]  

  • 46. Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms.
    Verbeek R; Sandhu MS; Hovingh GK; Sjouke B; Wareham NJ; Zwinderman AH; Kastelein JJP; Khaw KT; Tsimikas S; Boekholdt SM
    J Am Coll Cardiol; 2017 Mar; 69(11):1513-1515. PubMed ID: 28302296
    [No Abstract]   [Full Text] [Related]  

  • 47. Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease.
    Stein EA; Raal F
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):101-8. PubMed ID: 26861250
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lp(a) lipoprotein--coping with heterogeneity.
    Scanu AM
    N Engl J Med; 2003 Nov; 349(22):2089-90. PubMed ID: 14645635
    [No Abstract]   [Full Text] [Related]  

  • 49. Lipoprotein(a) in various conditions: to keep a sense of proportions.
    Kronenberg F
    Atherosclerosis; 2014 May; 234(1):249-51. PubMed ID: 24612688
    [No Abstract]   [Full Text] [Related]  

  • 50. [One year observation of natural course of aortic valve stenosis in patients with normal and abnormal lipoprotein (a) plasma level].
    Swierszcz J; Dubiel JS; Milewicz T; Sztefko K; Galicka-Latała D; Pfitzner R; Wodniecki J; Krzysiek J
    Przegl Lek; 2010; 67(3):161-4. PubMed ID: 20687376
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aortic stenosis: an atherosclerotic disease?
    Wierzbicki A; Shetty C
    J Heart Valve Dis; 1999 Jul; 8(4):416-23. PubMed ID: 10461242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Calcific aortic valve stenosis: degeneration or atherosclerosis?].
    Kaden JJ; Haase KK; Borggrefe M
    Dtsch Med Wochenschr; 2001 Apr; 126(14):405-7. PubMed ID: 11332244
    [No Abstract]   [Full Text] [Related]  

  • 53. Lipoprotein(a) and atherosclerotic disease in insulin-dependent diabetic patients with declining glomerular filtration rate.
    Earle KA; Mattock M; Morocutti A; Aravanitis D; Viberti GC
    Diabet Med; 1996 Dec; 13(12):1071-2. PubMed ID: 8973890
    [No Abstract]   [Full Text] [Related]  

  • 54. Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans.
    Arsenault BJ; Dubé MP; Brodeur MR; de Oliveira Moraes AB; Lavoie V; Kernaleguen AE; Guauque-Olarte S; Mathieu P; Pibarot P; Messika-Zeitoun D; Bossé Y; Rhainds D; Rhéaume E; Tardif JC
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):457-62. PubMed ID: 24334872
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lipoprotein(a) and risks of cardiovascular disease.
    Ridker PM; Hennekens CH
    Ann Epidemiol; 1994 Sep; 4(5):360-2. PubMed ID: 7981842
    [No Abstract]   [Full Text] [Related]  

  • 56. [Correlation between body mass index, lipoprotein (a) level and positive family history of cardiovascular diseases in children and adolescents with obesity, hypertension and diabetes].
    Głowińska B; Urban M; Koput A
    Pol Merkur Lekarski; 2002 Feb; 12(68):108-14. PubMed ID: 11995245
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is lipoprotein(a) cholesterol a significant indicator of cardiovascular risk?
    Nauck M; März W; Wieland H
    Clin Chem; 2000 Mar; 46(3):436-7. PubMed ID: 10702541
    [No Abstract]   [Full Text] [Related]  

  • 58. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk.
    Nordestgaard BG; Tybjærg-Hansen A
    Curr Opin Lipidol; 2011 Apr; 22(2):113-22. PubMed ID: 21358543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Lipoprotein(a) in children with hypercholesterolemia as a marker of the familial history of cardiovascular risk. The Working Group on Cardiovascular Risk Factors in Childhood and Adolescence].
    Sánchez Bayle M; Baeza Mínguez J; Vila Dupla S; Ruiz-Jarabo Quemada C; Asensio Antón J; Arnaiz P; Martín F
    An Esp Pediatr; 1996 Jul; 45(1):53-6. PubMed ID: 8849131
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Molecular genetics of cardiovascular diseases].
    Schunkert H; Hense HW
    Dtsch Med Wochenschr; 1995 Apr; 120(15):533-9. PubMed ID: 7720536
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.